Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
A phase 3 trial of Pamidronate in Multiple myeloma, run by Nordic Myeloma Study Group, completed.
Overview
Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month is a phase 3 interventional study registered as NCT00376883 by Nordic Myeloma Study Group, with 500 participants recorded, started 2000-01. Interventions recorded: pamidronate. Conditions recorded: Multiple Myeloma.
Linked to the drug Pamidronate because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialCombination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
Shares Pamidronate, Multiple myeloma and the tag pipeline.
- TrialDexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Shares Pamidronate, Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialMeasurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.